Cushing's syndrome: overview of clinical presentation, diagnostic tools and complications
This article discusses clinical presentation of CS with an eye on the most frequent cortisol-related comorbidities and discuss the main pitfalls of first- and second-line test in endogenous hypercortisolism diagnostic workup.
Publication date: Available online 27 March 2020Source: Nutrition, Metabolism and Cardiovascular DiseasesAuthor(s): Feiyan Liu, Yu Liu, Xizhuo Sun, Zhaoxia Yin, Honghui Li, Kunpeng Deng, Yang Zhao, Bingyuan Wang, Yongcheng Ren, Xuejiao Liu, Dongdong Zhang, Xu Chen, Cheng Cheng, Leilei Liu, Dechen Liu, Guozhen Chen, Shihao Hong, Chongjian Wang, Ming Zhang, Dongsheng Hu
Publication date: Available online 27 March 2020Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Roberto Laza-Cagigas, Shirley Chan, Daniel Sumner, Tarannum Rampal
Publication date: March–April 2020Source: Diabetes &Metabolic Syndrome: Clinical Research &Reviews, Volume 14, Issue 2Author(s):
Conclusions: Our results demonstrate that patients successfully treated for CS could develop autoimmune diseases. Therefore, after treatment, CS patients need to be strictly monitored in order to evaluate the possible onset of autoimmune diseases. PMID: 30662460 [PubMed]
Abstract The intention of the paper is to give rationale and to suggest enlisting Cushing's syndrome (CS) amongst high cardiovascular (CV) risk conditions. A considerable amount of data refers to several-fold amplified mortality in CS. The causes are based on high occurrence of many CV risk factors in persons with CS (e.g., adiposity, arterial hypertension, dyslipidemia, as well as diabetes mellitus /DM/). Therefore, practically all individuals with CS have correspondingly the metabolic syndrome (MetSy), which is known as laden with high CV risk. Characteristically, in spite of the young average age, numerous of C...
Short and long-term treatment with corticosteroids is widely used in clinical practice. Their chronic application not only elicits the well-documented positive responses on therapeutic targets but frequently induces features of iatrogenic Cushing syndrome. One of its main features is abdominally centered weight gain accompanied by features of the metabolic syndrome like hypertension and insulin resistance. These unwanted effects vary dependent on the dose and on the individual ’s sensitivity to glucocorticoids.
Authors: Ferraù F, Korbonits M Abstract Cushing's syndrome (CS), including visceral obesity, dyslipidemia, hypertension and diabetes among its many manifestations, is "a model" of metabolic syndrome. Glucocorticoid (GC) excess, through a combination of effects on liver, muscle, adipose tissue and pancreas, increases gluconeogenesis and impairs insulin sensitivity, leading to carbohydrate abnormalities. Dyslipidemia is a common finding in CS as a consequence of GC-related increased lipolysis, lipogenesis and adipogenesis. CS patients experience typical changes in body composition, with fat redistrib...
Publication date: Available online 10 May 2016 Source:The Lancet Diabetes & Endocrinology Author(s): Rosario Pivonello, Andrea M Isidori, Maria Cristina De Martino, John Newell-Price, Beverly M K Biller, Annamaria Colao Cushing's syndrome is a serious endocrine disease caused by chronic, autonomous, and excessive secretion of cortisol. The syndrome is associated with increased mortality and impaired quality of life because of the occurrence of comorbidities. These clinical complications include metabolic syndrome, consisting of systemic arterial hypertension, visceral obesity, impairment of glucose metabolism, ...
CONCLUSION: Indications to LA in case of AI and SCS is strongly supported by the presence of an associated metabolic syndrome. In spite of a limited number, our experience confirms the favourable results of surgery in such patients. KEY WORDS: Adrenal incidentaloma, Laparoscopic adrenalectomies, Subclinical Cushing syndrome. PMID: 26567723 [PubMed - in process]
CONCLUSION: Laparoscopic adrenalectomy seems to be beneficial in reversing several metabolic effects of hypercortisolism, with a low morbidity rate. However, the heterogeneity and low quality of the available studies preclude definitive recommendations. PMID: 25640696 [PubMed - as supplied by publisher]